S'abonner

Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis - 04/12/15

Doi : 10.1016/j.jaci.2015.04.024 
Melody C. Carter, MD a, , Sarah T. Clayton, BS a, Hirsh D. Komarow, MD a, Erica H. Brittain, PhD b, Linda M. Scott, NP a, Daly Cantave, MSN c, Donna M. Gaskins, BSN a, Irina Maric, MD d, Dean D. Metcalfe, MD a
a Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md 
b Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md 
c Department of Nursing, Clinical Center, National Institutes of Health, Bethesda, Md 
d Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md 

Corresponding author: Melody C. Carter, MD, Building 10/11C207, 10 Center Dr, MSC 1881, Bethesda, MD 20892-1881.

Abstract

Background

The management of children with pediatric mastocytosis poses a challenge. This is because there is limited information as to the application of clinical and laboratory findings and bone marrow histopathology as they relate to medical intervention and communication.

Objective

We sought to examine clinical aspects of pediatric mastocytosis in relationship to serum tryptase levels and bone marrow pathology to provide practical guidance for management.

Methods

Between 1986 and 2012, 105 children were evaluated at the National Institutes of Health. Organomegaly was confirmed by means of ultrasound. Baseline tryptase levels and at least 1 subsequent tryptase measurement was available in 84 and 37 of these children, respectively. Fifty-three children underwent a bone marrow examination. These data were used to examine relationships between clinical findings, tryptase levels, and marrow histopathology.

Results

In patients with high tryptase levels and severe mediator symptoms, all with organomegaly had systemic disease, and none without organomegaly had systemic disease. Serum tryptase levels differed significantly between patients with urticaria pigmentosa and those with diffuse cutaneous (P < .0001) and systemic mastocytosis (P < .0001) and in all 3 categories versus control subjects (P < .0001). Tryptase levels and symptoms decreased over time in most patients, and tryptase levels correlated with bone marrow mast cell burden in patients with systemic mastocytosis (P < .0001). There was a significant relationship between clinical resolution and the percentage decrease in tryptase levels (P = .0014).

Conclusions

The majority of children experienced major or complete disease resolution (57%), whereas the remainder exhibited partial improvement. Organomegaly was a strong indicator of systemic disease. Serum tryptase levels furthered classification and reflected clinicopathologic findings, while sequential tryptase measurements were useful in supplementing clinical judgment as to disease course.

Le texte complet de cet article est disponible en PDF.

Key words : Mast cells, tryptase, urticaria pigmentosa, cutaneous mastocytosis, diffuse cutaneous mastocytosis, mastocytosis, bone marrow examination

Abbreviations used : DCM, ISM, NIH, PTT, SM, UP, WHO


Plan


 Supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2015  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 136 - N° 6

P. 1673 - décembre 2015 Retour au numéro
Article précédent Article précédent
  • Genome-wide interaction study of gene-by-occupational exposure and effects on FEV1 levels
  • Kim de Jong, Judith M. Vonk, Wim Timens, Yohan Bossé, Don D. Sin, Ke Hao, Hans Kromhout, Roel Vermeulen, Dirkje S. Postma, H. Marike Boezen
| Article suivant Article suivant
  • The diversity of Bet v 1–specific IgG4 antibodies remains mostly constant during the course of birch pollen immunotherapy
  • Brinda Subbarayal, Dirk Schiller, Christian Möbs, Wolfgang Pfützner, Beatrice Jahn-Schmid, Barbara Gepp, Heimo Breiteneder, Stefan Vieths, Barbara Bohle

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.